CASP1 and metabolic disease: In this scenario, anti-IL-1 therapies proved to have therapeutic effect in inhibiting proinflammatory caspase-1, pathogenic element characteristic for CMS, and associated with aberrant inflammasome signaling, resulting in a new horizon for metabolic diseases treatment.